2022
DOI: 10.1016/j.jconrel.2022.06.003
|View full text |Cite
|
Sign up to set email alerts
|

Unlocking the potential of drug-drug cocrystals – A comprehensive review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 29 publications
(15 citation statements)
references
References 66 publications
0
13
0
1
Order By: Relevance
“…Recent research suggests that changes in polymer chain lengths may offer an efficient approach for generating cocrystal polymorphisms . What’s more, some biocompatible polymers may also be employed as additives to increase the bioavailability of cocrystals without separation, which is a new windfall for the pharmaceutical industry …”
Section: Strategies Of Mechanochemistrymentioning
confidence: 99%
“…Recent research suggests that changes in polymer chain lengths may offer an efficient approach for generating cocrystal polymorphisms . What’s more, some biocompatible polymers may also be employed as additives to increase the bioavailability of cocrystals without separation, which is a new windfall for the pharmaceutical industry …”
Section: Strategies Of Mechanochemistrymentioning
confidence: 99%
“…Cocrystal preparation processes include solid-state grinding, solution-reaction crystallization, solvent evaporation, and slurry conversion, and have all been extensively reported to date. Numerous synthesis techniques have been utilized for the creation of pharmaceutical cocrystals [ 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ]. In addition, pharmaceutical cocrystals are easier to produce than ECCs.…”
Section: New Energetic Cocrystalsmentioning
confidence: 99%
“…Pharmaceutical cocrystals mean cocrystals in which one component is an active pharmaceutical ingredient (API) and the others are called coformers. , Pharmaceutical cocrystals are emerging as a new strategy in drug development to improve the properties of APIs, such as solubility, dissolution rate, and hygroscopicity . Additionally, drug–drug cocrystals formed by two drugs can be expected to yield synergistic effects . For example, Novartis’ blockbuster anti-heart failure drug Entresto is a drug–drug cocrystal formed by sacubitril and valsartan …”
Section: Introductionmentioning
confidence: 99%
“…4 Additionally, drug−drug cocrystals formed by two drugs can be expected to yield synergistic effects. 5 For example, Novartis' blockbuster anti-heart failure drug Entresto is a drug−drug cocrystal formed by sacubitril and valsartan. 6 Despite the huge advantages of pharmaceutical cocrystals, selecting appropriate coformers is the first key issue faced by chemists.…”
Section: Introductionmentioning
confidence: 99%